May 3 – 6, 2019
December 4 – 6, 2019
Renaissance Washington DC
December 2 – 4, 2020
Publication date: March 2019
Source: Urologic Oncology: Seminars and Original Investigations, Volume 37, Issue 3
Author(s): Thomas Martini, Jakob Heinkele, Roman Mayr, Cleo-Aron Weis, Felix Wezel, Sarah Wahby, Markus Eckstein, Thomas Schnöller, Johannes Breyer, Ralph Wirtz, Manuel Ritter, Christian Bolenz, Philipp Erben
Author(s): Charbel Chalouhy, Sandeep Gurram, Reza Ghavamian
Lymph node dissection is part of the standard treatment protocol for various cancers, but its role in prostate cancer has been debatable for some time. Pelvic lymphadenectomy has been shown to better help stage prostate cancer patients, but has yet to be definitively proven to be of any benefit for survival. Various templates for lymph node dissections exist, and though some national guidelines have endorsed an extended pelvic node dissection, the choice of template is still controversial. Pelvic lymphadenectomy may lead to a slightly higher rate complications and operative time, and their use must be judiciously applied to patients with a high enough risk of lymph node involvement. We present a comprehensive review of the literature regarding the benefits and harms of lymph node dissection in prostate cancer.
Author(s): Mounsif Azizi, Juan Chipollini, Charles C. Peyton, Salim K. Cheriyan, Philippe E. Spiess
Penile squamous cell carcinoma is a rare cancer in men. The main prognosticators of survival for penile cancer patients remain the presence and the extent of lymph node metastasis. While radical inguinal lymphadenectomy has been the cornerstone of regional lymph node management for many years, it is still associated with significant morbidity and psychological distress. Recent developments in penile squamous cell carcinoma management have been met with some controversy in the urologic oncology community. Herein, we review the current controversies and developments on the role of inguinal lymphadenectomy for penile cancer.